Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tax Inversions and Price Attacks: Will Wyden Make the Link?

This article was originally published in RPM Report

Executive Summary

Finance Committee Chair Ron Wyden is promising immediate action to stop the trend of biopharma companies acquiring ex-US firms to reincorporate for tax reasons. The prospects for legislation are limited – but will the debate open up a new angle to attack biopharma pricing in the US?

You may also be interested in...



Sen. Warren’s “War on Pharma”: Rhetorical Blast, But Remarkably Limited Objectives

Despite her reputation as a populist, anti-corporate crusader, Elizabeth Warren did not focus on Big Pharma in her first years in the Senate. The headlines following a speech by Warren last week suggest that has changed – but the actual legislative proposal looks a lot different than the rhetoric makes it sound.

Pharma’s Adherence Allies: Part D Hearing Underscores Industry Progress in Reframing Rebate Debate

Sen. Bill Nelson is the primary sponsor of legislation to impose rebates on Medicare Part D. But when he held a hearing on the program in his Aging Committee, something surprising happened: everyone wanted to talk about adherence instead.

‘A Forever Battle:’ Patent Reform, Launch Prices, And Where Lower Rx Price Advocates Will Go Next

Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel